SLC5A2 and bacterial urinary tract infection: In a meta-analysis of 58 studies, SGLT2 inhibitors increased the risk of UTI and genital infection compared to placebo (odds ratio [OR] 1.34, 95% CI 1.03–1.74, and OR 3.50, 95% CI 2.46–4.99, respectively)23.